腸チフスワクチン接種
WordNet
- serious infection marked by intestinal inflammation and ulceration; caused by Salmonella typhosa ingested with food or water (同)typhoid_fever, enteric_fever
- the scar left following inoculation with a vaccine
PrepTutorEJDIC
- 腸チフス / 腸チフスの
- 〈C〉〈C〉(…の)種痘,ワクチン接種,予防注射 / 〈C〉種痘の跡
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/06/22 22:35:17」(JST)
[Wiki en表示]
Not to be confused with typhus vaccine.
Typhoid vaccine
| Vaccine description |
| Target disease |
Typhoid |
| Clinical data |
| AHFS/Drugs.com |
monograph |
| MedlinePlus |
a607028 |
| Legal status |
? |
| Identifiers |
| CAS number |
Y |
| ATC code |
J07AP01 J07AP02 J07AP03 |
| N (what is this?) (verify) |
Typhoid vaccines are vaccines developed to prevent typhoid fever.
There are two effective types:[1]
- Ty21a, which is a live vaccine given orally
- Vi capsular polysaccharide vaccine, which is an injectable subunit vaccine
Ty21a is licensed for use from age six years and older. Boosters are recommended every 5 years.[2] The Vi capsular polysaccharide vaccine is licensed for use from age two years and older, and boosters are required every three years.[3]
Almroth Edward Wright developed an effective inactivated whole-cell typhoid vaccine that was introduced in 1896.[1] Due to side-effects its usage was eventually discontinued.[3]
An experimental vaccine called Vi-rEPA has showed promising results in trials so far, indicating higher effectiveness and longer immunity. However, it has yet to be licensed for use.[1]
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[4]
Available preparations
- Vi polysaccharide vaccine: Typhim Vi® (Sanofi Pasteur); Typherix® (GSK)[3]
- Combined hepatitis A/Vi polysaccharide vaccine: ViATIM® (Sanofi Pasteur); Hepatyrix® (GSK)[3]
- Ty21a oral vaccine: Vivotif® (Crucell)[3]
References
- ^ a b c Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L (2007). "Vaccines for preventing typhoid fever". Cochrane Database Syst Rev (3): CD001261. doi:10.1002/14651858.CD001261.pub2. PMID 17636661.
- ^ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142807.pdf
- ^ a b c d e Salisbury, D; Ramsay, M; Noakes, K. ""Chapter 33: Typhoid"". Immunisation against infectious disease. Department of Health. p. 418. ISBN 0-11-322528-8.
- ^ "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
|
Artificial induction of immunity / Immunization: Vaccines, Vaccination, and Inoculation (J07)
|
|
| Development |
- Adjuvants
- List of vaccine ingredients
- Mathematical modelling
- Timeline
- Trials
|
|
| Classes |
- Conjugate vaccine
- DNA vaccination
- Inactivated vaccine
- Live vector vaccine
- Attenuated vaccine
- Heterologous vaccine
- Subunit/component / Peptide / Virus-like particle
- Toxoid
|
|
| Administration |
- Global:
- GAVI Alliance
- Policy
- Schedule
- Vaccine injury
- USA:
- ACIP
- Vaccine court
- Vaccines for Children Program
- VAERS
- VSD
|
|
| Vaccines |
|
Bacterial
|
- Anthrax
- Brucellosis
- Cholera#
- Diphtheria#
- Hib#
- Lyme disease‡
- Meningococcus#
- MeNZB
- NmVac4-A/C/Y/W-135
- NmVac4-A/C/Y/W-135 - DT
- Pertussis#
- Plague
- Pneumococcal#
- Q fever
- Tetanus#
- Tuberculosis
- Typhoid#
- Typhus
- combination: DTwP/DTaP
|
|
|
Viral
|
- Adenovirus
- Flu#
- Hantavirus
- Hepatitis A#
- Hepatitis B#
- HPV
- Japanese encephalitis#
- Measles#
- Mumps#
- Polio#
- Rabies#
- Rotavirus#
- Rubella#
- Smallpox
- Tick-borne encephalitis
- Varicella zoster
- Yellow fever#
- combination:
- research:
- Cytomegalovirus
- Epstein–Barr
- Hepatitis C
- HIV
|
|
|
Protozoan
|
|
|
|
Helminthiasis
|
|
|
|
Other
|
- Cancer vaccines
- ALVAC-CEA
- Hepatitis B#
- HPV (Cervarix · Gardasil)
- NicVAX
- TA-CD
- TA-NIC
|
|
|
| Controversy |
- General
- MMR
- NCVIA
- Pox party
- Simpsonwood
- Thiomersal
- Andrew Wakefield
- Autism omnibus trial
|
|
| See also |
- Epidemiology
- Eradication of infectious diseases
- List of vaccine topics
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
gr+f/gr+a (t)/gr-p (c)/gr-o
|
drug (J1p, w, n, m, vacc)
|
|
|
|
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drug (dnaa, rnaa, rtva, vacc)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers.
- Roggelin L1, Vinnemeier CD2, Fischer-Herr J3, Johnson-Weaver BT4, Rolling T5, Burchard GD6, Staats HF7, Cramer JP8.
- Vaccine.Vaccine.2015 Jul 2. pii: S0264-410X(15)00753-7. doi: 10.1016/j.vaccine.2015.05.080. [Epub ahead of print]
- An injectable Vi-capsular polysaccharide vaccine against typhoid fever is available but vaccine-induced immunity tends to wane over time. The phenomenon of immunotolerance or hyporesponsiveness has earlier been described for polysaccharide vaccines such as pneumococcal capsular polysaccharide vaccin
- PMID 26144902
- Quantitative Magnetization Transfer Imaging as a Biomarker for Effects of Systemic Inflammation on the Brain.
- Harrison NA1, Cooper E2, Dowell NG3, Keramida G2, Voon V4, Critchley HD5, Cercignani M6.
- Biological psychiatry.Biol Psychiatry.2015 Jul 1;78(1):49-57. doi: 10.1016/j.biopsych.2014.09.023. Epub 2014 Oct 14.
- BACKGROUND: Systemic inflammation impairs brain function and is increasingly implicated in the etiology of common mental illnesses, particularly depression and Alzheimer's disease. Immunotherapies selectively targeting proinflammatory cytokines demonstrate efficacy in a subset of patients with depre
- PMID 25526971
- Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.
- Domingos-Pereira S1, Hojeij R1, Reggi E1, Derré L1, Chevalier MF1, Romero P2, Jichlinski P1, Nardelli-Haefliger D1.
- Oncoimmunology.Oncoimmunology.2015 May 22;4(7):e1016697. eCollection 2015.
- The efficacy of antitumoral responses can be increased using combinatorial vaccine strategies. We recently showed that vaccination could be optimized by local administration of diverse molecular or bacterial agents to target and augment antitumoral CD8 T cells in the genital mucosa (GM) and increase
- PMID 26140240
Japanese Journal
- Modelling typhoid risk in Dhaka Metropolitan Area of Bangladesh: the role of socio-economic and environmental factors
- Corner Robert J,Dewan Ashraf M,Hashizume Masahiro
- International Journal of Health Geographics 12, 13, 2013-03-16
- … BackgroundDeveloping countries in South Asia, such as Bangladesh, bear a disproportionate burden of diarrhoeal diseases such as Cholera, Typhoid and Paratyphoid. … This study considers a range of both census data and spatial data from other sources, including remote sensing, as potential predictors of typhoid risk. … Typhoid data are aggregated from hospital admission records for the period from 2005 to 2009. …
- NAID 120005537565
- 国内で市販されていない海外渡航者用ワクチン(腸チフス及び髄膜炎菌ワクチン)への需要と接種希望者の検討
- 高山 直秀
- 感染症学雑誌 : 日本伝染病学会機関誌 : the journal of the Japanese Association for Infectious Diseases 79(4), 254-259, 2005-04-20
- NAID 10015684328
- 国内で市販されていない海外渡航者用ワクチン (腸チフス及び髄膜炎菌ワクチン) への需要と接種希望者の検討
- 高山 直秀
- 感染症学雑誌 79(4), 254-259, 2005
- 近年海外赴任などの目的で出国する日本人の数は増加している.多くが渡航先にしているアジア地域などでは, 日本では発生がないかまれな感染症が常在している.こうした疾患のうち, 腸チフスと髄膜炎菌感染症は, 有効なワクチンが実用化されて予防可能となっているが, 日本では未認可のため入手困難である.国内で腸チフスワクチンと髄膜炎菌ワクチンに対する需要がどの程度であるかを知るためにアベンティス・パストゥール …
- NAID 130004331257
Related Links
- Vaccination against typhoid fever is recommended if you are travelling to parts of the world where typhoid the condition is common. ... Vaccination against typhoid fever is recommended if you are travelling to parts of the world where ...
- Typhoid fever is a systemic infection caused by the Gram-negative bacillus Salmonella typhi . Most salmonella types only cause local infection of the gastrointestinal... ... Indications for S. typhi vaccination Travellers to areas where ...
★リンクテーブル★
[★]
- 関
- enteric fever、typhi、typhoid fever、typhus